ConvaTec Group PLC (LON:CTEC - Get Free Report) insider Tobias Hestler purchased 50,000 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of GBX 226 per share, with a total value of £113,000.
ConvaTec Group Stock Up 2.6%
Shares of LON:CTEC opened at GBX 232.80 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.93 and a debt-to-equity ratio of 121.83. ConvaTec Group PLC has a 52-week low of GBX 193 and a 52-week high of GBX 259.30. The stock's fifty day simple moving average is GBX 212.78 and its 200-day simple moving average is GBX 220.93. The company has a market capitalization of £4.55 billion, a P/E ratio of 27.07, a P/E/G ratio of 0.93 and a beta of 0.77.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. Citigroup decreased their price target on shares of ConvaTec Group from GBX 250 to GBX 230 and set a "neutral" rating on the stock in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday. UBS Group restated a "buy" rating and set a GBX 375 target price on shares of ConvaTec Group in a research report on Monday, May 18th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a GBX 315 target price on shares of ConvaTec Group in a research note on Monday. Finally, Berenberg Bank reiterated a "buy" rating and issued a GBX 340 price target on shares of ConvaTec Group in a report on Tuesday, April 21st. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of GBX 306.
Read Our Latest Report on CTEC
About ConvaTec Group
(
Get Free Report)
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ConvaTec Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.
While ConvaTec Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
